| RELMADA THERAPEUT.DL-,001 |
| USA |
| Gesundheit |
| US75955J4022 / A2PSZF |
| 4E2 (Frankfurt) / RLMD (NASDAQ) |
| FRA:4E2, ETR:4E2, 4E2:GR, NASDAQ:RLMD |
| - |
| https://www.relmada.com/ |
|
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders. Its current pipeline centers on product candidates designed to address areas of significant unmet m..
>Volltext.. |
| 407.53 Mio. EUR |
| 228.59 Mio. EUR |
| - |
| -61.61 Mio. EUR |
| -59.6 Mio. EUR |
| -0.68 EUR |
| - |
| 5.19 Mio. EUR |
| -47.05 Mio. EUR |
| 25.99 |
| - |
| -21.14% |
| - |
| - |
| - |
| - |
| RELMADA |
| 16.11.26 |